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Abstract
Background: To assess the effects of apolipoprotein E (ApoE) ε4 genotype on amyloid-β (Aβ) and tau burden and
their longitudinal changes in Alzheimer’s disease (AD) spectrum.
Methods: Among 272 individuals who underwent PET scans (18F-florbetaben for Aβ and 18F-flortaucipir for tau)
and ApoE genotyping, 187 individuals completed 2-year follow-up PET scans. After correcting for the partial volume
effect, we compared the standardized uptake value ratio (SUVR) for Aβ and tau burden between the ε4+ and ε4−
groups. By using a linear mixed-effect model, we measured changes in SUVR in the ApoE ε4+ and ε4− groups.
Results: The ε4+ group showed greater baseline Aβ burden in the diffuse cortical regions and greater tau burden
in the lateral, and medial temporal, cingulate, and insula cortices. Tau accumulation rate was higher in the parietal,
occipital, lateral, and medial temporal cortices in the ε4+ group. In Aβ+ individuals, baseline tau burden was greater
in the medial temporal cortex, while Aβ burden was conversely greater in the ε4− group. Tau accumulation rate
was higher in the ε4+ group in a small region in the lateral temporal cortex. The effect of ApoE ε4 on enhanced
tau accumulation persisted even after adjusting for the global cortical Aβ burden.
Conclusions: Progressive tau accumulation may be more prominent in ε4 carriers, particularly in the medial and
lateral temporal cortices. ApoE ε4 allele has differential effects on the Aβ burden depending on the existing
amyloidosis and may enhance vulnerability to progressive tau accumulation in the AD spectrum independent of
Aβ.
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Background
Except for the rare dominantly inherited Alzheimer’s
disease (AD), most AD patients are sporadic [1, 2]. The
apolipoprotein E (ApoE) gene encodes a 35-kDa extra-
cellular lipid and cholesterol carrier glycoprotein, and its
ε4 allele is a major genetic risk factor for sporadic AD
[1, 3]. The presence of this allele increases the risk of
AD in a dose-dependent manner and lowers the age at
onset [4, 5]. However, its effect on the regional accumu-
lation rates of two major pathological proteins—amyl-
oid-β (Aβ) and tau—remains unclear.
Greater amounts of Aβ burden were observed in ε4
carriers than in non-carriers in previous postmortem
and 11C-Pittsburgh compound B (PIB) positron emission
tomography (PET) studies [6–8]. Longitudinal change in
Aβ burden was also greater in ε4 carriers than non-
carriers in some previous studies [9–11], while another
longitudinal study did not find this association [12].
Postmortem studies showed more frequent neurofib-
rillary tangle pathology in ε4 carriers in a dose-
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dependent manner [7], a greater tangle pathology in AD
patients with ε4 homozygotes [13], and an association of
the ε4 allele with tangle pathology in the presence of Aβ
[14]. In contrast, another study did not find evidence for
these associations [15]. A recent 18F-flortaucipir PET
study demonstrated that ApoE ε4 had an Aβ-
independent effect on the increase in the tau load in the
entorhinal cortex and hippocampus [16], while the other
studies found this effect was associated with the global
Aβ burden [17] or even greater tau burden in the pro-
dromal AD and AD dementia patients without the ε4 al-
lele, particularly in the parietal cortex, than in patients
who carried the ε4 allele [18].
In this study, we investigated the effects of the ε4 allele
on regional Aβ and tau burden and their longitudinal
changes in cognitively unimpaired (CU) individuals, mild
cognitive impairment (MCI) patients, and AD patients.
Materials and methods
Participants
From January 2015 to August 2017, 272 individuals
completed a baseline tau PET study at Gangnam Sever-
ance Hospital. The baseline study included magnetic res-
onance (MR) and two PET scan (18F-florbetaben for Aβ
and 18F-flortaucipir for tau) studies, neuropsychological
tests using Seoul Neuropsychological Screening Battery
(tests for global cognition and six cognitive domains)
[19], and ApoE genotyping. In 187 individuals who
agreed to a follow-up study, the same neuroimaging and
neuropsychological tests were performed after a mean of
2.0 ± 0.3 years.
We used the clinical diagnostic criteria for probable
AD dementia proposed by the National Institute of
Neurological and Communicative Disorders and Stroke,
and used the Alzheimer’s Disease and Related Disorders
Association and Petersen’s criteria for diagnosing MCI
[20, 21]. Accordingly, the baseline study included 96 CU,
105 MCI, and 71 AD dementia patients, and the longitu-
dinal study included 80 CU, 42 MCI, and 65 AD demen-
tia patients. Baseline Aβ-positivity was determined by
two nuclear medicine specialists using the validated vis-
ual assessment methods [22, 23]. Detailed information
for the inclusion of participants has been described in
our previous reports [24, 25].
Acquisition of PET and MR images
We performed 18F-florbetaben and 18F-flortaucipir PET
in separate days, almost within a month (8.3 ± 7.9 days
for the baseline and 9.4 ± 7.6 days for the follow-up
scans). PET images were acquired in a Biograph mCT
PET/CT scanner (Siemens Medical Solutions; Malvern,
PA, USA) for 20 min at 90 min after the injection of 18F-
florbetaben and at 80 min after the injection of 18F-flor-
taucipir. Prior to the scan, brain computed tomography
images were acquired for attenuation correction. 3D
PET images were reconstructed using the ordered-
subsets expectation maximization (OSEM) algorithm in
a 256 × 256 × 223 matrix with a 1.591 × 1.591 × 1mm
voxel size. MR images were scanned within 90 days be-
fore or after the acquisition of 18F-flortaucipir PET
(27.7 ± 25.7 days for the baseline and 13.4 ± 18.0 days for
the follow-up scans). In a 3.0-T MR scanner (Discovery
MR750, GE Medical Systems, Milwaukee, WI), T1-
weighted MR images were acquired using 3D-spoiled
gradient-recalled sequences (repetition time = 8.3 ms,
echo time = 3.3 ms, flip angle = 12°, 512 × 512 matrix,
voxel spacing 0.43 × 0.43 × 1mm).
Image processing steps
We used FreeSurfer 5.3 (Massachusetts General Hos-
pital, Harvard Medical School; http://surfer.nmr.mgh.
harvard.edu) software to obtain participant-specific
volumes-of-interest (VOIs). In brief, T1-weighted MR
images were resliced to a 1-mm isovoxel space in Free-
Surfer, corrected for inhomogeneity, and segmented into
gray and white matter. After tessellation, 3D surfaces for
gray and white matter were reconstructed. Subcortical
regions were segmented with the probabilistic registra-
tion method [26], and cortical regions were probabilis-
tically labeled based on the curvature information
overlaid on an inflated white matter surface [27, 28]. Fi-
nally, participant-specific composite VOI images, includ-
ing 16 and 4 subcortical regions, were created by
merging anatomically related regions. Detailed list of
VOIs and their corresponding regions in the Desikan-
Killiany atlas was presented in Table S1.
Statistical parametric mapping 12 (Wellcome Trust
Centre for Neuroimaging, London, UK) and in-house
software implemented in MATLAB 2015b (MathWorks,
Natick, MA, USA) were used for the processing of PET
images. PET images were first coregistered to MR im-
ages that had been resliced to the FreeSurfer isovoxel
space. Using participant-specific composite VOI images,
PET images were corrected for partial volume effect
(PVE) with a region-based voxel-wise (RBV) method
[29]. The standardized uptake value ratio (SUVR) images
were created using the cerebellar crus median obtained
by overlaying a template mask on PET images spatially
that were normalized with diffeomorphic anatomical
registration through an exponentiated lie algebra tool
[30]. Finally, regional SUVR values were obtained by
overlaying the participant-specific composite VOI im-
ages on individual PET images.
For visualization, cortical uptake values were mapped
on the white matter surface by assigning the values of
voxels corresponding to the mid-point between the gray
and white matter surface, corrected for PVE with the
RBV method, and then converted to SUVR maps using
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the cerebellar crus median as a reference. Surface SUVR
images were spatially normalized and finally smoothed
on a 2D surface using a Gaussian kernel with 8-mm full-
width half-maximum.
Statistical analysis
SPSS 23 (IBM Corp., Armonk, NY, USA) was used for
the statistical analysis of demographic data and baseline
VOI data. Continuous and categorical demographic vari-
ables were compared between the ApoE ε4− and ε4+
groups using independent t test and chi-square test, re-
spectively. Using the general linear model with age, years
of education, sex, and baseline Mini-Mental State Exam-
ination (MMSE) scores as covariates, the baseline SUVR
values were compared between the ApoE ε4− and ε4+
groups. P values for trends were calculated using analysis
of covariance (ANCOVA) after adjusting for age, sex,
years of education, and baseline MMSE scores as covari-
ates. We included MMSE scores as a covariate in all
statistical analysis due to the difference in the distribu-
tion of cognitive status between the ε4+ and ε4− groups.
Region-wise multiple comparisons were corrected for
using Benjamini-Hochberg’s false discovery rate (FDR)
method (FDR-corrected P < 0.05 for 17 regions) [31].
Likewise, baseline surface images were compared be-
tween the two groups using the same general linear
model implemented in FreeSurfer. Longitudinal changes
in the regional SUVR values and surface images were
compared between the groups using a linear mixed-
effect model in MATLAB with age, sex, years of
education, baseline MMSE scores, and an interaction
term between the presence of ApoE ε4 and time inter-
vals as fixed factors, under the assumption of a random
intercept and slope, by setting the intervals and subject
as random factors.
We primarily analyzed data with four covariates above
and repeated the analysis with the baseline global cor-
tical Aβ burden as an additional covariate.
Results
Demographic characteristics
Baseline and follow-up demographic data are summa-
rized in Table 1 and S2. In individuals included in the
baseline and follow-up studies, age, sex, and education
did not differ between the ε4− and ε4+ groups. The ε4+
group showed higher proportions of Aβ-positivity and
clinical dementia, and worse global cognition at baseline
than the ε4− group. However, none of the demographic
characteristics and global cognition differed between
each groups stratified by Aβ-positivity. Compared to
baseline, global cognition had worsened at follow-up in
both the ε4− and ε4+ groups. The number of ε4 carriers
was greater in patients with dementia than that in CU
and MCI patients.
Baseline Aβ and tau burden
In all 272 Aβ− and Aβ+ individuals, the ApoE ε4+ group
exhibited greater Aβ burden in the global cortex; pre-
frontal, parietal, lateral temporal, parahippocampal, and
cingulate cortices; and hippocampus than the ε4− group,
and all regions survived correcting for multiple compari-
sons. Conversely, in 114 Aβ+ individuals, Aβ burden was
greater in the ε4− group in the global cortex, and sen-
sorimotor, superior parietal, occipital, and insula cortices
than in the ε4+ group, although all regions did not sur-
vive correcting for multiple comparisons (Fig. 1a).
Table 1 Baseline demographic characteristics of 272 participants who completed the baseline study
Aβ± Aβ− Aβ+
ε4− ε4+ ε4− ε4+ ε4− ε4+
N 195 77 134 24 61 53
Baseline age (years) 70.4 ± 10.3 70.0 ± 8.6 68.4 ± 10.3 65.5 ± 8.3 74.7 ± 8.7 72.1 ± 7.9
Females (%) 127 (65%) 51 (66%) 90 (67%) 16 (67%) 37 (61%) 35 (66%)
Education (years) 11.1 ± 4.9 11.2 ± 5.0 11.0 ± 4.9 11.4 ± 4.2 11.2 ± 4.8 11.1 ± 5.3
Duration (years) 2.6 ± 1.5 3.1 ± 1.4 2.3 ± 1.5 2.4 ± 1.3 3.0 ± 1.5 3.2 ± 1.4
Aβ-positivity (%) 61 (31%) 53 (69%)a 0 (0%) 0 (0%) 61 (100%) 53 (100%)
ε2/2:ε2/3:ε3/3 1:37:157 n.a. 1:31:102 n.a. 0:6:55 n.a.















MMSE 25.4 ± 4.7 23.5 ± 5.3a 26.8 ± 3.2 26.7 ± 2.5 22.2 ± 5.7 22.1 ± 5.7
CDR-SB 1.6 ± 2.3 2.7 ± 2.5a 0.9 ± 1.5 0.8 ± 1.4 3.1 ± 3.0 3.6 ± 2.4
Data are presented as mean ± SD
Abbreviations: CU cognitively unimpaired, MCI mild cognitive impairment, DEM dementia, Aβ± Aβ-positivity, ApoE apolipoprotein E, MMSE Mini-Mental State
Examination, CDR-SB Clinical Dementia Rating sum-of-boxes
aP < 0.05 for the comparisons between the ε4− and ε4+
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Surface-based statistics showed similar results as VOI-
based comparisons (Fig. 1b).
In all individuals, greater tau burden was observed
in the ε4+ group in the lateral and medial temporal,
cingulate, and insula cortices, and all regions survived
multiple comparisons (Fig. 1a). In Aβ+ individuals,
the ε4+ group showed greater tau burden in the
medial temporal regions, of which only the amygdala
and hippocampus survived correcting for multiple
comparisons. Surface-based statistics showed greater
tau burden in the medial temporal and anterior cin-
gulate regions in the ε4+ group than in the ε4−
group; however, none of the regions survived after
correcting for multiple comparisons (Fig. 1b).
Fig. 1 Comparison of baseline 18F-florbetaben and 18F-flortaucipir SUVR between the ApoE ε4− and ε4+ groups. a VOI-based comparisons
between the ApoE ε4− and ε4+ groups. Data are presented as means (dots) and standard deviations (error bars) of the ε4− (blue) and ε4+ (red)
groups. P values for the comparison between the ε4− and ε4+ groups are expressed as -Log10P. Red bars represent the regions that survived
correcting for region-wise multiple comparisons (false discovery rate-corrected P < 0.05), and blue dotted lines represent uncorrected P = 0.05. b
Surface-based comparisons between the ApoE ε4− and ε4+ groups. Regions surrounded by white lines (ε4− < ε4+ in Aβ and tau burden in all
individuals) represent the cortical areas that survived correcting for multiple comparisons (false discovery rate-corrected P < 0.05). P values for the
comparison between the ε4− and ε4+ groups are expressed as -Log10P. Aβ±, Aβ-positivity; ApoE, apolipoprotein E; SUVR, standardized uptake
value ratio; A, 18F-florbetaben; T, 18F-flortaucipir
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Increased baseline Aβ burden in the hippocampus was
associated with the number of ε4 alleles. Likewise, tau
burden in the medial temporal regions showed an asso-
ciation with ε4 allele in a dose-dependent manner
(Fig. 5a). In Aβ+ individuals, increased tau burden in the
hippocampus and amygdala was associated with the ε4
allele in a dose-dependent manner (Fig. 5b).
We also compared baseline SUVR values between the
two ApoE groups within each group for cognitive status
(Fig. 2). When compared to the ε4− group, tau burden
was greater in the ε4+ group in the hippocampus in Aβ+
MCI patients and in the hippocampus and amygdala in
Aβ+ AD dementia patients. However, all regions did not
survive correction for multiple comparisons.
When the baseline global cortical Aβ burden was in-
cluded as an additional covariate in the model, the ApoE
ε4+ group exhibited greater tau burden in all medial
temporal regions when compared to the ε4− group
(Additional file 1: Fig. S2A).
Longitudinal changes in Aβ and tau burden
Examples of baseline Aβ and tau burden and their
changes at follow-up are demonstrated in Fig. 3. In all
187 individuals, the ε4+ group exhibited a higher Aβ ac-
cumulation rate than the ε4− group in the global cortex;
superior parietal, occipital, lateral temporal, and parahip-
pocampal cortices; and amygdala; however, none of the
regions survived correcting for multiple comparisons
(Fig. 4a). A surface-based comparison showed a higher
Aβ accumulation rate in diffuse cortical areas in the ε4+
group than in the ε4− group, and small regions in the
lateral temporal cortex survived correcting for multiple
Fig. 2 Comparison of baseline 18F-florbetaben (a) and 18F-flortaucipir (b) SUVR values between the ApoE ε4− and ε4+ groups in each group for
cognitive status. Blue and light blue bars represent the -Log10P for ApoE ε4− > ε4+, and red and light red bars represent the -Log10P for ApoE ε4
− < ε4+. Blue and red bars represent the regions that survived after correcting for multiple comparisons (false discovery rate-corrected P < 0.05),
and blue dotted lines represent uncorrected P = 0.05
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comparisons (Fig. 4b). In Aβ+ individuals, there was no
difference in the Aβ accumulation rate between the two
groups.
In all individuals, the tau accumulation rate in the
ε4+ group was higher in the global cortex, and pre-
frontal, parietal, occipital, lateral and medial temporal,
posterior cingulate, and insula cortices compared to
the ε4− group. Except for the prefrontal, superior
parietal, and posterior cingulate cortices, all regions
survived correcting for multiple comparisons (Fig. 4a).
Moreover, the increase in tau accumulation rate is as-
sociated with the number of ApoE ε4 allele (Fig. 5b).
Similar to the VOI-based results, a surface-based
comparison of the annual increase in tau showed a
higher tau accumulation rate, particularly in the dif-
fuse parietotemporal cortex in the ε4+ group (Fig. 4b).
In Aβ+ individuals, the ε4+ group exhibited a greater
annual increase in tau burden in the middle temporal
and hippocampus, although none of the regions sur-
vived correcting for multiple comparisons (Fig. 4a).
Surface-based statistics also showed a higher tau ac-
cumulation rate in small regions in the basal and lat-
eral temporal and sensorimotor cortices even after
correction for multiple comparisons (Fig. 4b).
Even after inclusion of the baseline global cortical Aβ
burden as an additional covariate in the model, the re-
sults for the VOI-based comparison of tau accumulation
rates between the two ApoE groups were almost similar
(Additional file 1: Fig. S2B).
Discussion
In this study, we assessed the effects of the ApoE ε4
genotype on Aβ and tau burden and found a greater
baseline Aβ and tau burden and higher tau accumulation
rate in the ε4+ group than in the ε4− group. The Aβ ac-
cumulation rate in the ε4+ group was higher in small
areas in the lateral temporal cortex. In Aβ+ individuals,
the baseline tau burden in the ε4+ group was greater in
the medial temporal regions and the tau accumulation
rate in the ε4+ group was higher in small regions in the
Fig. 3 Spaghetti plots showing individual changes in regional SUVR values. In 187 Aβ± individuals, the individual data points measured at
baseline and follow-up are displayed as color-coded dots (cyan = Aβ−/ApoE ε4−, green = Aβ−/ApoE ε4+, orange = Aβ+/ApoE ε4−, red = Aβ+/
ApoE ε4+). Aβ±, Aβ-positivity; ApoE, apolipoprotein E; SUVR, standardized uptake value ratio; A, 18F-florbetaben; T, 18F-flortaucipir
Baek et al. Alzheimer's Research & Therapy          (2020) 12:140 Page 6 of 12
basal and lateral temporal cortices than in the ε4−
group.
A transgenic mouse model with neuron-specific over-
expression of ApoE ε4 showed greater phosphorylated
tau burden in the neocortex and hippocampus [32], and
tau transgenic mice expressing human ApoE ε4
exhibited greater tau burden in the hippocampus than
those expressing ε2 or ε3 [33]. A postmortem study
showed that ε4 gene dose-dependently increased neuro-
fibrillary tangle (NFT) pathology, and there was greater
NFT pathology in diffuse cortical areas in AD patients
carrying the ε4 allele than in those who did not [7].
Fig. 4 Comparison of annual changes in 18F-florbetaben and 18F-flortaucipir SUVR between the ApoE ε4− and ε4+ groups. a VOI-based
comparison between the ApoE ε4− and ε4+ groups. Data are presented as means (dots) and standard deviations (error bars) of the ε4− (blue)
and ε4+ (red) groups. P values for the comparison between the ε4− and ε4+ groups are expressed as -Log10P. Red bars represent the regions
that survived correcting for region-wise multiple comparisons (false discovery rate-corrected P < 0.05), and blue dotted lines represent
uncorrected P = 0.05. b Surface-based comparisons between the ApoE ε4− and ε4+ groups. Regions surrounded by white lines (ε4− < ε4+ in Aβ
and tau accumulation rates in all individuals, and ε4− < ε4+ in tau accumulation rate in Aβ+ individuals) represent the cortical areas that survived
correcting for multiple comparisons (false discovery rate-corrected P < 0.05). P values for the comparison between the ε4− and ε4+ groups are
expressed as -Log10P. P values for the comparison between the baseline and follow-up are expressed as -Log10P. Aβ±, Aβ-positivity; ApoE,
apolipoprotein E; SUVR, standardized uptake value ratio; A, 18F-florbetaben; T, 18F-flortaucipir
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Fig. 5 P for trend analysis of baseline 18F-florbetaben and 18F-flortaucipir SUVR and their longitudinal accumulation rates across the ApoE ε4-
negative, heterozygous, and homozygous groups. Data are presented as means and standard deviations (error bars) of ε4-negative (blue), ε4-
heterozygous (green), and ε4-homogygous (red) groups. Regions that showed significant differences in a dose-dependent manner after adjusting
for sex, age, duration of education, and MMSE score (uncorrected P for trend < 0.05) and additionally survived correcting for region-wise multiple
comparisons (false discovery rate-corrected P < 0.05) are presented as red bars. Blue dotted lines represent uncorrected P for trend = 0.05.
Rightward direction of horizontal bars represents an SUVR value increased with higher numbers of ε4 alleles, while the leftward direction
represents an SUVR value decreased with higher numbers of ε4 alleles. Aβ±, Aβ-positivity; ApoE, apolipoprotein E; SUVR, standardized uptake
value ratio; A, 18F-florbetaben; T, 18F-flortaucipir
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Another study showed greater cortical NFT pathology
only in the AD patients homozygous for the ε4 allele
than in those with a single ε4 allele or those without the
allele [13]. Unlike these transgenic mice and human
postmortem studies, human cerebrospinal fluid (CSF)
biomarker studies showed no differences in the level of
CSF T-tau and P-tau between the ε4+ and ε4− groups
[34, 35]. Moreover, one cross-sectional 18F-flortaucipir
PET study in Aβ+ MCI and AD patients demonstrated
that the ε4− group conversely exhibited greater tau bur-
den in the parieto-occipital cortex than the ε4+ group
[18]. In our Aβ+ AD dementia patients, the ε4− group
tended to show greater tau burden in the parieto-
occipital cortex, similar to the previous study, while the
ε4+ group tended to show greater tau burden in the
medial temporal cortex. However, none of these regions
survived correction for multiple comparisons (Fig. 2b).
This discrepancy may be attributable to the dispropor-
tionate frequency of the ε4 allele in patients with differ-
ent subtypes of AD. The hippocampal sparing type of
AD is associated with a younger age at onset, lower fre-
quency of the ApoE ε4 allele, greater tau burden particu-
larly in the parietal cortex, faster cortical atrophy, and
faster cognitive decline than the typical AD subtype
[36–39]. Therefore, we suspect that inclusion of a
greater proportion of the hippocampal sparing subtype
in the study cohort diluted the effect of ε4 on the tau
burden or may even have caused contrary results.
Although a previous report has demonstrated a longi-
tudinal increase in CSF tau in AD patients [40], one lon-
gitudinal 18F-flortaucipir PET study performed in a
small number of AD patients did not find an association
between the ApoE genotypes and longitudinal changes
in tau burden [41]. In our results for all Aβ± individuals,
the regional tau accumulation rate was higher in diffuse
regions in the medial and lateral temporal and parieto-
occipital cortices in the ε4+ group than in the ε4−
group. Moreover, even in Aβ+ individuals, a higher tau
accumulation rate was observed in the ε4+ group in
small regions in the temporal cortex, suggesting that the
ApoE ε4 genotype had an effect on progressive tau
accumulation.
One recent 18F-flortaucipir PET study including 325
individuals (90% cognitively unimpaired and 10% cogni-
tively impaired) showed an association of ApoE ε4 with
increased tau burden in the entorhinal cortex, but statis-
tical significance was lost after adjusting for global cor-
tical Aβ burden [17]. In contrast, another study that
included 489 individuals with a more balanced distribu-
tion of cognitive status (57% cognitively unimpaired and
43% cognitively impaired) demonstrated that ApoE ε4
had an effect on the increased tau burden in the entorhi-
nal cortex and hippocampus, and which persisted even
after adjusting for global cortical Aβ burden, as we
found in our study [16]. Moreover, the effect of ApoE ε4
on progressive tau accumulation was replicated after
adjusting for global cortical Aβ burden in our longitu-
dinal study. To evaluate the proportion of a direct effect
of ApoE ε4+ for increasing regional tau burden, we add-
itionally performed path analysis with the ApoE ε4 posi-
tivity as a predictor and global cortical Aβ burden as a
mediator. There was a significant direct effect of ApoE
ε4 on baseline tau burden in the medial temporal re-
gions, and 49–66% of total effect was explained by direct
effect. Likewise, a significant direct effect of ApoE ε4 on
progressive tau accumulation in longitudinal study was
observed in the lateral temporal and parahippocampal
cortices and hippocampus, and 64–71% of total effect
was explained by direct effect (Additional file 1: Table
S3). Therefore, tau accumulation may be accelerated in
the presence of ApoE ε4 independent of Aβ burden.
The ApoE ε4 isoform was more likely to stimulate
neuronal Aβ production than the other isoforms in vitro
[42], and transgenic mice expressing the ApoE ε4 iso-
form showed less effective clearance of soluble Aβ from
brain interstitial fluid [43]. Human autopsy findings
demonstrated greater Aβ burden in the ε4+ than in the
ε4− group not only in AD patients [13], but also in the
MCI patients and CU individuals [44]. Likewise, when
compared to individuals without the ε4 allele, a greater
Aβ burden was observed in the global cortex in CU indi-
viduals and in MCI patients with the ε4 allele [8], and in
the temporo-parietal cortex in AD patients with ε4 allele
based on the PET studies [45]. Our study also demon-
strated greater Aβ burden in the diffuse cortical areas in
individuals with the ε4 allele than in those without. In
contrast to the strong association between the ε4 allele
and the baseline Aβ burden, we found a weak effect of
ApoE ε4 on progressive Aβ accumulation in small re-
gions in the lateral temporal cortex only in all Aβ± indi-
viduals. The Aβ accumulation rate in Aβ+ individuals
did not differ between the ε4+ and ε4− groups like pre-
vious studies [9, 11], suggesting an effect of the ApoE ε4
allele on Aβ deposition only in the early stage of the
disease.
Interestingly, Aβ burden in the Aβ+ individuals was
paradoxically greater in the ε4− group than in the ε4+
group, similar to previous 11C-PIB and 18F-fluorodeoxy-
glucose PET studies that demonstrated lower Aβ burden
and contrarily greater cortical hypometabolism in the
AD patients carrying the ε4 allele than in those without
this allele [46, 47]. This paradoxical effect of the ApoE
ε4 allele on Aβ deposition can be expected by clinical
studies that found an impact of the ApoE ε4 allele on
Aβ burden in CU and MCI but not in those with AD [8,
34]. Furthermore, a study with transgenic mice demon-
strated enhanced Aβ aggregation by ApoE ε4 in the early
seeding stage but not in the later Aβ growth stage [48].
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An in vitro experiment demonstrated that ApoE ε4
binds to toxic Aβ oligomers and more potently delays
further aggregation of Aβ into the PET-detectable fibril
form than the other ApoE isoforms [49]. Therefore,
ApoE ε4 may play an important role in Aβ accumulation
in the early stages of AD pathogenesis rather than in the
advanced stages and may be more likely to be exposed
to toxic oligomers. Subsequently, events toward final
neurodegeneration may be induced, thereby shifting the
hypothetical biomarker curves for tau and neurodegen-
eration to the Aβ curve [47]. It is also interesting to note
that a transgenic mice model expressing both Aβ and
tau exhibited a smaller number of plaques than a model
expressing only Aβ [50]. Greater microgliosis and reduc-
tion of the amyloid-precursor protein-producing neu-
rons due to greater tau accumulation in ε4 carriers may
be another possible mechanism underlying the paradox-
ically lower Aβ burden [50]. However, this hypothesis
cannot fully explain the mechanism due to the mismatch
between the cortical areas with greater Aβ burden in the
ε4− group and those with greater tau burden in the ε4+
group (Fig. 1).
Limitations
Our study showed greater tau burden in the medial
temporal areas in all Aβ+ individuals carrying the ε4
allele than in those not carrying the ε4 allele, but the
result for the hippocampus was limited by the off-
target binding in the choroid plexus adjacent to the
hippocampus. In addition, distribution of diagnoses
was different between the ε4+ and ε4− groups, with
global cognition being more impaired in the ε4+
group (Table 1). Consequently, we had to adjust for
global cognition additionally in the group comparison
to minimize the effect of differences in disease sever-
ity between groups. Another methodological limitation
was the high variability and bias in the quantitation
of longitudinal PET study with simple ratio method
due to changes in perfusion [51]. Finally, a longer
follow-up duration will be necessary to observe
greater differences in progressive tau accumulation
between the ε4+ and ε4− groups.
Conclusions
Our study revealed that progressive tau accumulation
may occur more prominently in ε4 carriers, particu-
larly in the medial and lateral temporal cortices. The
presence of the ε4 allele not only has differential ef-
fects on Aβ burden depending on the existing amyl-
oidosis but also possibly enhances vulnerability to
progressive tau accumulation in the AD spectrum in-
dependent of Aβ.
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